Since it is an enzyme that is critical for viral replication and its cleavage specificity is very distinct from the known human proteases, NSP5 is an attractive drug target for treating COVID-19.14 As the most abundant viral protein during SARS-CoV-2 infection, the N protein contains the N-terminal domain (NTD) and the C-terminal domain (CTD), which are primarily responsible for RNA binding and critical for viral genome assembly into the virions.15 Therefore, the N protein is another appealing antigen and drug target. The gene discussed is SPECC1; the disease is COVID-19.